Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax First Quarter 2023 Earnings Conference Call. Today's call is being recorded.
Syndax Pharmaceuticals Inc (SNDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Avidity Partners Management David Witzke And Michael Gregory | 3,865,300 | $81,635,136 | -35% | 2.7% |
| 2. | Kynam Capital Derrick Tang | 3,205,986 | $67,710,424 | +26% | 8.74% |
| 3. | VenBio Select Advisor Kurt Von Emster | 2,650,000 | $55,968,000 | 0.82% | |
| 4. | Eversept Partners Kamran Moghtaderi | 2,209,057 | $46,655,284 | +37% | 4.07% |
| 5. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,143,197 | $45,264,321 | +48% | 1.65% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.46 | 500 | 15,666 | 2021-04-26 | Filing | ||
| $14.11 | 13,967 | 43,300 | 2021-04-22 | Filing | ||
| $8.00 | 12,500 | 43,900 | 2020-02-04 | Filing | ||
| $5.40 | 11,000 | 31,400 | 2019-10-10 | Filing | ||
| $7.29 | 7,200 | 20,400 | 2019-05-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.18 | 28,273 | 17,836 | 2023-06-09 | Filing | ||
| $21.18 | 24,582 | 46,109 | 2023-06-09 | Filing | ||
| $21.41 | 52,855 | 17,836 | 2023-05-09 | Filing | ||
| $19.53 | 52,855 | 17,836 | 2023-04-10 | Filing | ||
| $22.53 | 52,854 | 17,836 | 2023-03-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 7,003,734 | $147,918,861 | 0.02% | |
| 2. | 4,900,841 | $103,505,761 | 0% | |
| 3. | 3,866,230 | $81,654,538 | 0% | |
| 4. | 3,708,838 | $78,330,659 | 5.67% | |
| 5. | 3,497,085 | $73,858,436 | 0% |
News See All
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2022 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter 2022 Conference Call. Today's call is being recorded.
10 Best Stocks to Buy According to Ari Zweiman’s 683 Capital Partners
In this article, we present the list of top 10 stock picks of Ari Zweiman’s 683 Capital Partners at the end of the second quarter.
Top 5 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying
Below we present the list of the top 5 healthcare stocks the experts at Sphera Global Healthcare Fund are buying.
Hedge Funds Are Crazy About Syndax Pharmaceuticals, Inc. (SNDX)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
Should I Avoid Syndax Pharmaceuticals, Inc. (SNDX)?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
10 Best Biotech Stocks to Buy According to Alan Frazier's Frazier Healthcare Partners
In this article, we discuss the 10 best biotech stocks to buy according to Alan Frazier.
Syndax Pharmaceuticals, Inc. (SNDX) Fell Out Of Favor With Hedge Funds
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a...
Is SNDX Stock A Buy or Sell?
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...
Hedge Funds Are Truly Crazy About Syndax Pharmaceuticals, Inc. (SNDX)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Billionaire Hedge Funds
